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ABSTRACT 
Objective: The main purpose of this study was to develop a simple, precise, rapid and accurate RP-HPLC method for the quantitative determination 
of ticagrelor in human plasma.  
Methods: The separation was accomplished by the isocratic method by utilizing phenomenex C18 column on a Shimadzu binary gradient liquid 
chromatography system furnished with LC-20AD solvent delivery system, SPD-20-A photo-diode array detector and 20 µl loop volume in a 
rheodyne injector. The analyte was extracted by protein precipitation in the involvement of diethyl ether as a protein precipitator. The mobile phase 
was developed for the estimation of the drug in human plasma consists of acetonitrile and methanol in the ratio of 60:40% v/v. Separation was done 
with a flow rate of 1 ml/min at a detection wavelength of 254 nm. 
Results: Retention time was found to be 4.503 min with a run time 10 min. Linearity shows in a range of 20-100 µg/ml, with a correlation 
coefficient of 0.9992 respectively. Stability studies of ticagrelor in plasma were carried out by, short term stability, long term stability and bench top 
stability studies. Short term stability, long term stability and bench top stability of ticagrelor was carried out from 20 and 100 µg/ml concentration 
and %RSD was ascertained 0.12% and 0.08%, 0.18% and 0.15%, 1.19% and 1.30% respectively. 
Conclusion: The outcomes were observed to be inside the knowledge of ICH guidelines. The prepared solution was injected in triplicate, and % RSD 
was measured. Acquired results demonstrate that proposed strategy can be effortlessly and advantageously applied for routine examination of 
ticagrelor in human plasma. 
Keywords: Bioanalytical method, Reverse phase HPLC, Ticagrelor, ICH 




Bioanalysis is the strategy used to determine the concentration of 
drug and metabolites in the biological matrices like plasma, serum, 
cerebrospinal fluid, urine, saliva etc. Bioanalytical method and 
validation are utilized to build up, that a quantitative analytical 
method can be connected for the biochemical process. Validation 
involves documentation of laboratory investigations that the method 
is suitable and reliable for the intended applications [1]. It is utilized 
for the assessment of bioavailability and bioequivalence studies, 
quantitative evaluation of drug and metabolites, new drug 
development, clinical pharmacokinetics, research process and 
therapeutic drug monitoring. Bioanalytical techniques are 
constantly undergoing changes and improvements that they are the 
cutting edge of technology [2]. 
Ticagrelor is an anti-platelet drug which is chemically (1S,2S,3R,5S)-3-[7-
[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propyl thiol)-3H-
[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-hydroxyethoxy)cyclopentane-
1,2-diol. It blocks adenosine diphosphate (ADP) receptors of subtype 
P2Y12 in contrast to other antiplatelet drugs, ticagrelor has a binding 
site making it an allosteric antagonist and the blockage is reversible [3]. 
It inhibits platelet aggregation and thrombus formation in 
atherosclerotic disease by preventing the activation of platelet [4]  
The present study portrays the improvement and acceptance of a 
delicate, particular, fast, straight forward and cost effective HPLC 
bioanalytical strategy for ticagrelor in human plasma as indicated by 
ICH Q2 (R1) and EMA guidelines [5, 6]. The objective of validation of 
bioanalytical procedure is to demonstrate that it is suitable for the 
intended purpose and it will be beneficial for the researchers. 
MATERIALS AND METHODS 
Chemicals and reagents 
The active pharmaceutical ingredients were benevolently acquired 
from swapnaroop drugs and pharmaceuticals, Maharashtra, India. 
The pharmaceutical formulations were purchased from the local 
market which contains ticagrelor 90 mg. required chemicals, 
reagents, acetonitrile, methanol used are of HPLC grade. 
Optimization of chromatographic conditions 
Separation was done by using phenomenex C18 (250 × 4.6 mm, 5 
µm) column on a shimadzu liquid chromatographic system with LC-
20AD solvent delivery system, SPD-20A photodiode array detector 
and rheodyne injector with 20 µl loop volume. Mobile phase consists 
of a mixture of acetonitrile and methanol in the ratio of 60% v/v in 
pump A and 40% v/v in pump B was found to be the most suitable 
mobile phase for ideal chromatographic separation of ticagrelor. It 
was pumped with a flow rate of 1.0 ml/min through the column. The 
column was equilibrated by pumping the mobile phase for 30 min 
prior to the injection of the drug solution. The detection of the drug 
was monitored at 254 nm. The run time was set at 10 min. 
Preparation of stock solution 
Blood samples were collected and centrifuged at 10,000 rpm for 2 
min. The plasma thus obtained were separated and stored. 1 mg of 
standard ticagrelor was weighed accurately and spiked into 1 ml 
plasma. After centrifugation, subsequent aliquots of 20-100 µg/ml 
concentrations were prepared by diluting with 100 µl of diethyl 
ether and the mobile phase and clear supernatant liquid of each 
concentration were injected for analysis and chromatogram were 
taken [7]. The chromatogram is shown in fig. 1. 
Calibration curve 
The calibration plots were constructed by plotting peak area against 
respective concentrations. Linearity was obtained by analysis of 
serially diluted sample in the range of 20, 40, 60, 80,100 µg/ml. 
Calibration graph is shown in fig. 2. 
Validation of the method 
The developed method was validated by evaluating linearity, 
precision, accuracy and specificity which were done in acceptance of 
ICH [8] and EMA guidelines. 
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Linearity  
Linearity was studied by standard solutions at different concentration 
levels. The linearity range for ticagrelor was found to be 20-100 µg/ml. 
The regression equation was found to be y = 35798x-9772.3 with a 
coefficient of correlation (r2
 
) 0.9992. The correlation coefficient for 
linearity is 0.9999. Since the result is approximately close to the true 
value, the method is indicated as highly significant. 
 
Fig. 1: Chromatogram of ticagrelor in human plasma 100 µg/ml 
 
 
Fig. 2: Calibration curve of ticagrelor in human plasma 
 
Table 1: Linearity of ticagrelor in human plasma 








Precision was determined by carrying three replicates of 
concentration 40 µg/ml and performed intraday (within a day) and 
interday (day to day) studies. The percentage relative standard 
deviation (%RSD) was found to be less than 1%. For Intraday 
precision study, evaluation was carried out by injecting a standard 
solution at various time intervals and %RSD of Ticagrelor was found 
to be 0.56% and 0.51% shown in table 2 where inter-day precision 
was carried out in consecutive days with %RSD of 0.76% and 0.81% 
shown in (table 3). The %RSD can be reached up to 2%.  
Since the outcome is less than 1% it was found to be satisfactory, 
which indicates method is precise [9]. 
 
Table 2: Intraday study of ticagrelor in human plasma 
Days Standard concentration Peak area 




MEAN 3217899.33 3219199 
STD DEV 18124.41 16575.51 
% RSD 0.56% 0.51% 
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Table 3: Interday study of ticagrelor in human plasma 
Standard concentration Peak area 




MEAN 1743466.66 1744042.66 
STD DEV 13175.13 14137.94 
% RSD 0.76% 0.81% 
 
Limit of detection (LOD) 
LOD was determined by standard deviation method and slope of the 
calibration plot by using the formula 3.3*σ/S. It was observed to be 
0.382µg/ml. since the observed concentration is low, the method is 
sufficiently sensitive. 
Limit of quantification (LOQ) 
LOD was determined by standard deviation method and slope of the 
calibration plot by using the formula 10* σ/S. It was observed to be 
1.158µg/ml. As the amount of analyte was found to be less, we can 
estimate the drug at very low concentration. 
Stability of ticagrelor in human plasma 
Short term stability 
Short term stability was determined by storing concentration of 20 
and100 µg/ml over a period of 6 h at room temperature. Stability 
was determined by performing three replicates and calculated % 
RSD. It was found to be 0.12% and 0.08% respectively, shown in 
table 4 as it is less than 1% the method is said to be stable. 
Long term stability 
Long-term stability was determined by storing concentration of 20 
and 100 µg/ml over a period of 10 d at room temperature. Stability 
was determined by calculating the % RSD. It was found to be 0.18% 
and 0.15% respectively, as it is less than 1% the method can said to be 
stable. 
Bench top stability 
Three replicates of the lowest and higher concentration were 
determined. The samples were assessed after keeping at room 
temperature (bench top) against freshly prepared concentrations 
and %RSD was calculated [10]. It was found to be 1.19% and 1.30% 
respectively. The %RSD can be reached up to 2%. Since the result is 
less than 2% values were found to be satisfactory, which indicates 
method is stable. 
 
Table 4: Short-term stability of ticagrelor 
Concentration Peak area  Mean Standard deviation %RSD 
20 1929188 1927512 2385.189 0.12% 
1922566 
1924781 




Table 5: Long-term stability of ticagrelor 
Concentration Peak area  Mean Standard deviation %RSD 
20 1152882 1153686 2065.306 0.18% 
1156032 
1152143 




Table 6: Bench top stability of ticagrelor 
Concentration Old Fresh % RSD 
20 1077812 1096036 1.19% 
100 5342790 5442090 1.30% 
 
CONCLUSION 
The developed RP-HPLC method was found to be simple, precise, 
accurate and sensitive for the estimation of Ticagrelor in human plasma. 
Validation of results according to ICH and EMA carried out revealed high 
accuracy and good precision. The RSD for every one of the parameters 
are observed to be short of what one, which shows the legitimacy of the 
technique is reasonably fine. A mixture of acetonitrile and methanol 
mobile phase ratio of 60% v/v in pump A and 40% v/v in pump B at a 
flow rate of 1 ml/min. The wavelength was found to be 254 nm in U. V 
spectroscopy. Retention time was found to be 4.503 min with a run time 
10 min. 20-100 µg/ml concentration of ticagrelor shows linearity with a 
correlation coefficient of 0.9992. Thus we can conclude that this method 
can be easily and conveniently adopted for the quality control analysis of 
ticagrelor in human plasma. 
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